glp-1 and insulin GLP-1-based therapies for type 2 diabetes: from single, dual triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome Targeting GLP-1, GIP & GCG

Pharmacologic analogues of GLP-1 were first approved for type 2 diabetes (T2D) in the mid-2000s (e.g

Diabetologia 50:19001909 Marx N, Burgmaier M, Heinz P et al (2010) Glucagon-like peptide-1(137) inhibits chemokine-induced migration of human CD4-positive lymphocytes

Its important to emphasize that much of this research is still in its early stages, and more robust human trials are needed to confirm these potential mental health benefits

Andrew Adams, Group Vice President of Molecule Discovery and Director of the Lilly Institutes of Genetic Medicine at Eli Lilly, concluded his presentation on the GLP-1 story with a seismic question: "Are GLP-1s the world's first longevity drug?" It was a watershed moment

At the general population level, AOMs will have a meaningful impact on mortality